Company Quick10K Filing
Haemonetics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 51 $6,085
10-Q 2020-02-04 Quarter: 2019-12-28
10-Q 2019-11-01 Quarter: 2019-09-28
10-Q 2019-08-06 Quarter: 2019-06-29
10-K 2019-05-22 Annual: 2019-03-30
10-Q 2019-02-05 Quarter: 2018-12-29
10-Q 2018-11-06 Quarter: 2018-09-29
10-Q 2018-08-07 Quarter: 2018-06-30
10-K 2018-05-23 Annual: 2018-03-31
10-Q 2018-02-06 Quarter: 2017-12-30
10-Q 2017-11-07 Quarter: 2017-09-30
10-Q 2017-08-07 Quarter: 2017-07-01
10-K 2017-05-24 Annual: 2017-04-01
10-Q 2017-02-06 Quarter: 2016-12-31
10-Q 2016-11-07 Quarter: 2016-10-01
10-Q 2016-08-01 Quarter: 2016-07-02
10-K 2016-06-01 Annual: 2016-04-02
10-Q 2016-02-02 Quarter: 2015-12-26
10-Q 2015-11-04 Quarter: 2015-09-26
10-Q 2015-07-30 Quarter: 2015-06-27
10-K 2015-05-22 Annual: 2015-03-28
10-Q 2015-02-05 Quarter: 2014-12-27
10-Q 2014-11-04 Quarter: 2014-09-27
10-Q 2014-07-31 Quarter: 2014-06-28
10-K 2014-05-22 Annual: 2014-03-29
10-Q 2014-01-30 Quarter: 2013-12-28
10-Q 2013-10-30 Quarter: 2013-09-28
10-Q 2013-08-02 Quarter: 2013-06-29
10-K 2013-05-20 Annual: 2013-03-30
10-Q 2013-02-01 Quarter: 2012-12-29
10-Q 2012-11-07 Quarter: 2012-09-29
10-Q 2012-08-08 Quarter: 2012-06-30
10-K 2012-05-22 Annual: 2012-03-31
10-Q 2012-02-06 Quarter: 2011-12-31
10-Q 2011-11-03 Quarter: 2011-10-01
10-Q 2011-08-10 Quarter: 2011-07-02
10-K 2011-05-26 Annual: 2011-04-02
10-Q 2011-02-08 Quarter: 2011-01-01
10-Q 2010-11-10 Quarter: 2010-10-02
10-Q 2010-08-11 Quarter: 2010-07-03
10-K 2010-06-01 Annual: 2010-04-03
10-Q 2010-02-03 Quarter: 2009-12-26
8-K 2020-02-04 Earnings, Exhibits
8-K 2020-01-13 Leave Agreement, Regulation FD, Exhibits
8-K 2019-11-01 Earnings, Exhibits
8-K 2019-08-26 Enter Agreement
8-K 2019-08-06 Earnings, Exhibits
8-K 2019-07-25 Shareholder Rights, Officers, Amend Bylaw, Shareholder Vote, Exhibits
8-K 2019-07-22 Regulation FD, Exhibits
8-K 2019-05-21 Regulation FD
8-K 2019-05-14 Impairments, Regulation FD, Exhibits
8-K 2019-05-07 Earnings, Exhibits
8-K 2019-04-23 Officers, Exhibits
8-K 2019-02-05 Earnings, Exhibits
8-K 2018-12-19 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-11-06 Earnings, Exhibits
8-K 2018-08-07 Earnings, Exhibits
8-K 2018-07-26 Shareholder Rights, Officers, Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-06-18 Enter Agreement, Leave Agreement, Off-BS Arrangement, Exhibits
8-K 2018-06-14 Officers
8-K 2018-05-08 Earnings, Exhibits
8-K 2018-02-06 Earnings, Exhibits
8-K 2018-01-24 Officers, Exhibits

Haemonetics Financials

HAE Metrics, Comps, Filings

Annual | Quarterly

Business

Haemonetics is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions to customers to help improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets including blood and plasma component collection, the surgical suite, and hospital transfusion services. When used in this report, the terms "we," "us," "our" and "the Company" mean Haemonetics.

Blood is essential to a modern healthcare system. Blood and its components (plasma, platelets and red cells) have many vital and frequently life-saving clinical applications. Plasma is used for patients with major blood loss and is manufactured into biopharmaceuticals to treat a variety of illnesses, including immune diseases and coagulation disorders. Red cells treat trauma patients or patients undergoing surgery with high blood loss, such as open heart surgery or organ transplant. Platelets have many uses in patient care, including supporting cancer patients undergoing chemotherapy.

Haemonetics develops and markets a wide range of devices and solutions to serve our customers. We provide plasma collection systems and software that enable the collection of plasma used by biopharmaceutical companies to make life saving pharmaceuticals and also provides analytical devices for measuring hemostasis that enable healthcare providers to better manage their patients' bleeding risk. In addition, Haemonetics makes blood processing systems and software that make blood donation more efficient and track life giving blood components. Finally, Haemonetics supplies systems and software that facilitate blood transfusions and cell processing.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Insulet (PODD) 7,136 66% 163.9 2% 978 728 661 435 17 47 7,624
Hill-Rom Holdings (HRC) 7,067 49% 25.9 5% 4,575 2,951 2,884 1,415 215 335 8,663
Haemonetics (HAE) 6,085 46% 35.9 4% 1,260 669 977 450 49 176 6,331
Penumbra (PEN) 6,047 67% 257.6 3% 585 131 495 332 15 23 5,969
Novocure (NVCR) 5,679 72% -357.0 -10% 406 247 294 212 -41 -16 5,646
ICU Medical (ICUI) 5,345 39% 39.5 3% 1,623 305 1,311 508 47 127 5,031
Integra Lifesciences (IART) 4,669 62% 20.6 3% 3,290 1,869 1,493 930 101 262 5,393
Globus Medical (GMED) 4,300 77% 18.9 10% 1,391 103 743 573 143 221 4,182
Cantel Medical (CMD) 3,630 47% 30.3 5% 1,070 409 918 427 55 126 3,816
Tandem Diabetes Care (TNDM) 3,601 52% -70.5 -22% 255 110 282 147 -55 -49 3,470
Merit Medical Systems (MMSI) 3,357 45% 26.4 2% 1,736 786 949 423 39 141 3,722
Nuvasive (NUVA) 3,283 72% 19.4 3% 1,805 1,127 814 52 194 3,765
Glaukos (GKOS) 2,779 87% -384.5 -4% 302 114 211 182 -12 -7 2,730
Nevro (NVRO) 1,957 69% -26.5 -21% 448 246 379 261 -93 -77 2,049
iRhythm Technologies (IRTC) 1,941 75% -48.5 -21% 207 159 182 137 -44 -40 1,923
Cardiovascular Systems (CSII) 1,490 81% 334.2 -0% 219 71 248 200 -0 4 1,416
Inspire Medical Systems (INSP) 1,451 82% -63.2 -14% 186 33 64 52 -25 -23 1,424
Atricure (ATRC) 1,174 73% -164.1 -6% 343 102 216 158 -20 -7 1,189
CryoLife (CRY) 1,123 66% 37.2 1% 597 315 271 179 3 35 1,307
Tactile Systems Technology (TCMD) 1,058 70% 68.0 7% 122 23 166 116 8 15 1,033

Balance Sheet ($MM)2011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-31
Cash197229179192161115140180169
Accounts Receivable127135170165146157153151185
Inventory84117184198211187177161194
PP&E156162257271322338324332344
Assets8339111,4621,5141,4851,3191,2391,2371,275
Accounts Payable283550544840435563
Long-Term Debt54480440430408316254350
Liabilities147179693676659598499485607
Stockholders' Equity686733769838826722740752668
Income Statement ($MM)2011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-31
Revenue677728892939910909886904968
Cost of Revenue321359464470476503508492550
Gross Profit355369428468434406378412418
R&D333744545445383936
SG&A214245323365334317302317298
Tax30231111187919
Net Income8067393517-56-264655
Cash Flow ($MM)2011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-31
Cash Operating12311585140127122160220159
Cash Investing-52-52-596-106-122-105-73-63-116
Cash Financing-18-30462-21-33-63-60-121-51